Pharma News

Woman of the Week: Novartis Gene Therapies’ Chris Fox

Welcome to the Woman of the Week podcast, a weekly discussion that illuminates the unique stories of women leaders who are catalyzing change throughout the life sciences industry. You can check out all our podcast episodes here.

When Novartis acquired AveXis and its spinal muscular atrophy drug Zolgensma in 2018, the move helped the company fine-tune its gene therapy strategy. Armed with AveXis’ technology that “transfers DNA into cells through viral vectors,” Novartis Gene Therapies — and its 30 products in the pipeline — brought Chris Fox on board as president just over a year ago to further refine its culture, encourage innovation, and reimagine the impact gene therapies can have around the world.

“We’re looking at both internal innovation and external innovation, and how we (can) take the skills and capabilities and translate those into a sustainable business,” she said. “We still have a lot more work to do on Zolgensma, so we’re looking to broaden our reach with innovative access agreements and prepping our launch in intrathecal.”

Fox, who stepped into the role after spending more than 25 years in the industry in a multitude of roles and therapeutic categories, has been impacted by the closeness of Novartis’ relationships to patients.

“When we send out Zolgensma to a patient, we memorialize that significant moment by putting handprints on the wall on our manufacturing site with the location and the date,” she said. “Now we’re following patients who are six, seven years into their journey who have been dosed in our first clinical trials and we keep up with their families. So, we learn about their new experiences. This affords us not only a powerful motivation, but an intimacy with their journey and all of the things that affect the patient and … their families. While I have been a part of many patients’ journeys, this is much, much more intimate.”

Tapping into her U.S. and international leadership experience in sales, marketing and commercial operations, Fox is expanding Novartis’ reach with gene therapies.

“We’re excited about more gene therapies coming to market,” she said. “(I think): How will we influence engagements with health ministers across the globe? How do we create a sustainable platform? Most governments and infrastructures (have) very different models of chronic treatments. I think of it like cracking the code and problem solving as we go. There’s no playbook for this, and I think that in and of itself is motivational.”

In this episode of the Woman of the Week podcast, Fox shares some of the best leadership advice she ever received, her approach to balancing work and life, and how taking a global role changed her career trajectory.

Welcome to the Woman of the Week podcast, a weekly discussion that illuminates the unique stories of women leaders who are catalyzing change throughout the life sciences industry. You can check out all our podcast episodes here.

Welcome to WoW, the Woman of the Week podcast by PharmaVoice, powered by Industry Dive.

In this episode, Taren Grom, editor-in-chief emeritus at PharmaVoice, meets with Chris Fox, president, Novartis Gene Therapies.

Taren: Chris, welcome to the WoW podcast program.

Chris: It’s my pleasure. Nice to meet you, at least virtually.

Taren: Exactly. Nice to meet you as well. Chris, you joined Novartis just more than a year ago. Can you please share a bit of your career journey that led you to your current executive position?

Chris: Sure. I have been in the industry about 25 years and I began as a sales rep working for Rhone-Poulenc Rorer. I’ve worked at diverse number of companies – Takeda, a couple of startups, Merck, most recently Amgen before Novartis, and led many, many different sizes of team, small and mighty and much larger in the thousands. I think one of the things that has contributed to my current interest in growth and development is really being with experience brought the roles across kind of the commercial continuum. I think that’s been probably my most favorite part leading me to now a really unique opportunity at Novartis Gene Therapies, kind of building on the success that the team has started before I got here.

Taren: It’s exciting. So tell me, how did you get into the pharma space? You started at RPR, which I was going to laugh and say, you have to be an industry veteran to know Rhone-Poulenc Rorer, right?

Source link
#Woman #Week #Novartis #Gene #Therapies #Chris #Fox

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *